Trabectedin mechanism of action: What's new?

Future Oncology

Volumn 9, Issue 12 SUPPL., 2013, Pages 5-10

  D'Incalci, Maurizio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

antitumor activity; mechanism of action; trabectedin; tumor microenvironment

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53; TRABECTEDIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL DEATH; CONFERENCE PAPER; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; MACROPHAGE; MONOCYTE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DNA DAMAGE; HUMANS; MACROPHAGES; NEOPLASMS; TETRAHYDROISOQUINOLINES; TUMOR MICROENVIRONMENT;

EID: 84887982748     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.207     Document Type: Conference Paper

References (12)

1. D'Incalci M., Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol. Cancer Ther. 9(8), 2157-2163 (2010).
2. Grosso F, Dileo P, Sanfilippo R et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur. J. Cancer 42(10), 1484-1490 (2006). (Pubitemid 43903160)
3. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8(7), 595-602 (2007). (Pubitemid 46995623)
4. Germano G, Frapolli R, Simone M et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 70(6), 2235-2244 (2010).
5. Germano G, Mantovani A, Allavena P. Targeting of the innate immunity/inflammation as complementary anti-tumor therapies. Ann. Med. 43(8), 581-593 (2011).
6. Germano G, Frapolli R, Belgiovine C et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23(2), 249-262 (2013).
7. Marchini S, Fruscio R, Clivio L et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur. J. Cancer 49(2), 520-530 (2013).
8. Gago F. Modelling and simulation: a computational perspective in anticancer drug discovery. Curr. Med. Chem. Anticancer Agents 4(5), 401-403 (2004). (Pubitemid 39199340)
9. Grohar PJ, Griffin LB, Yeung C et al. Ecteinascidin 743 interferes with the activity of EWS-Fli1 in Ewing sarcoma cells. Neoplasia 13(2), 145-153 (2011).
10. Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 167(2), 195-205 (2012).
11. Allavena P, Signorelli M, Chieppa M et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 65(7), 2964-2971 (2005). (Pubitemid 40490102)
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).